The LYCRA Company

Q1 Investor Presentation

June 6, 2022

Disclaimer

This presentation has been prepared by The LYCRA Company (the "Company"), and is provided solely for discussion purposes. This presentation is incomplete without reference to, and should be viewed in conjunction with, the oral briefing discussing the results presented herein and the corresponding quarterly report. Neither this presentation nor any of its contents may be disclosed or used for any other purpose without the prior written consent of The LYCRA Company.

The presentation does not purport to contain all of the information that an investor in the Company may desire. Neither the presentation nor its delivery to any interested party shall constitute an offer to sell, a solicitation of an offer to buy, or a recommendation that any person should proceed with any acquisition of or investment in, the Company or any securities of the Company.

This presentation includes operational and financial results for the quarter and year ended March 31, 2022. Certain of this information is based solely on management accounts and has not been reviewed or subject to audit procedures. Other information contained in this presentation reflects management estimates for periods prior to the consummation of the acquisition of The LYCRA Company. You should not place undue reliance on these estimates. Our financial information contained in this presentation has been prepared on a good faith basis based on internal reporting for the periods presented. The financial and operational information included in this presentation has not been prepared in a manner consistent with the financial information and results of operations included in the final offering memorandum related to the 7.500% Senior Secured Notes due 2025 and 5.375% Senior Secured Notes due 2023 issued by Eagle Intermediate Global Holding B.V. and Ruyi US Finance LLC (the "final offering memorandum"). Similarly, because the operational and financial results for the quarter ended March 31, 2022 included in this presentation are prepared based solely on management accounts and estimates and has not been subject to audit procedures, such information may not be prepared on a basis consistent with future bondholder reports.

The historical financial information included herein includes financial information that is not required by or presented in accordance with generally accepted accounting principles in the United States of America ("GAAP") or any other internationally accepted accounting principles, including "EBITDA" and "Adjusted EBITDA," and the Company's consolidated financial information for the three months ended March 31, 2021.

This presentation and the oral remarks made in connection therewith may contain financial projections and forward looking statements. Such projections and statements are based on estimates and assumptions of management of The LYCRA Company regarding the Company's future performance and operations. These forward looking statements appear in a number of places in this presentation and include statements regarding the Company's future financial position and results of operations, its strategy, plans, objectives, goals and targets, future developments in the markets in which it participates or is seeking to participate or anticipated regulatory changes in the markets in which it operates or intends to operate. In some cases, you can identify forward looking statements by terminology such as "aim," "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "forecast," "guidance," "intend," "may," "plan," "potential," "predict," "projected," "risk," "seek," "should," "target" or "will" or the negative of such terms or other comparable terminology. When considering these forward looking statements, you should keep in mind that a number of factors that are beyond the Company's control could cause actual results to differ materially from the results contemplated by any such forward looking statements including the risks detailed under the heading "Risk Factors" in the quarterly report and the preceding annual report. We believe that the expectations reflected in these forward looking statements are reasonable but we cannot assure you that these expectations will prove to be correct and such forward looking statements included in this presentation should not be unduly relied upon. These statements speak only as of the date made.

In furnishing the presentation, no Relevant Person undertakes any obligation, and no Relevant Person shall have any duty, to provide the recipient with access to any additional information or to update any information contained herein. Each Relevant Person expressly disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from the presentation. The Company and its affiliates, directors, officers, employees and agents (each a "Relevant Person") make no representation or warranty as to the accuracy or completeness of the presentation and shall have no liability for any representations or warranties (expressed or implied), financial projections, or forward-looking financial statements contained in, or omitted from, the presentation or any other written or oral communications. By accepting the presentation, the recipient of the presentation (i) agrees and undertakes that it shall not seek to sue or otherwise hold any Relevant Person liable in any respect for the provision of the presentation, the information contained in the presentation, or the omission of any information from the presentation, and (ii) warrants that it is a person to whom it is lawful to provide a copy of the presentation in accordance with the applicable laws of its jurisdiction.

These materials are not to be printed, saved or distributed.

Executive Summary


(Values in USD unless noted)

- Q1 '22 EBITDA was \$49 million, up \$21 million vs prior quarter and down \$8 million vs same quarter prior year.
- Higher margins but lower sales volumes in Q1 '22 compared to Q4 '21. The higher margins were driven by LYCRA HyFit[®] price increases realized in Q1 2022.
- Q1 '22 sales volumes were lower than expected driven by COVID impact in China through a combination of supply and logistical impacts on our customers in addition to lower local demand.
- Q1 '22 results reflect \$65 million increase in raw material costs, \$10 million higher energy costs and \$7 million higher freight costs driven by inflation.

Key Financial Metrics

(Values in millions of USD unless noted)

Consolidated Total Sales & Gross Margin




Note: EBITDA and Adjusted EBITDA are not required by or presented in accordance with GAAP or any other internationally accepted accounting principles. The financial information for the TERATHANE® business is internal management data and is not meant to represent a discontinued operations figure, or represent what may be removed from the consolidated financials after the closure. It includes allocated selling, general and administrative expenses and includes total revenue, cost of goods sold and other operating expenses, and gross profit on the sale of PTMEG to the downstream business which is eliminated at the consolidated level.



4

Financial Performance

(Values in millions of USD unless noted)



Note: EBITDA and Adjusted EBITDA are not required by or presented in accordance with GAAP or any other internationally accepted accounting principles.


Confidential to The LYCRA Company

The LYCRA Company

5

Volume and Revenue

(Values in millions of USD unless noted)



Volume (kit) & LYCRA® fiber Concentration¹





Constant currency prices measured against Q1 2021 FX rates have increased due to implementation of higher prices to offset higher raw material costs.

Note: Volumes are unaudited management estimates.

¹ LYCRA® fiber concentration reflects LYCRA® fiber and LYCRA HyFit® fiber combined volumes as a percentage of Spandex volumes.

Confidential to The LYCRA Company




- Overall volumes are expected to be lower in Q2 compared to Q1 due to weaker demand from consumers in China driven by lockdowns and uncertainty related to ongoing inflationary concerns with brands/retails and consumers.
- Declining cost for PTMEG, our main raw material, will be offset by continued higher energy costs and inflation on other raw materials.
- Some pricing pressure is expected to impact our branded fibers given the continued decline in generic prices combined with FX devaluation on both the euro and RMB.

The LYCRA Company

Appendix

Key Margin Drivers



Consolidated Statement of Operations

(Values in millions of USD unless noted)

	Three months ended March 31,			
	2022	2021		
Net sales	\$ 328	\$ 263		
Sales to related parties	7	5		
Total sales	335	268		
Royalty and licensing income, net	2	1		
Total revenue	337	269		
Cost of goods sold and other operating expenses	273	197		
Gross profit	64	72		
Selling, general and administrative expenses	30	30		
Research and development expenses	7	7		
Restructuring (income) expense	4	(28)		
Other (income), net	(11)	(10)		
Operating income	34	73		
Equity in (income) of affiliates	(2)	(2)		
Interest expense, net	19	20		
Income before income taxes	17	55		
Income tax expense	3	12		
Consolidated net income	14	43		
Net (income) attributable to noncontrolling interest	(1)	(2)		
Net income attributable to The LYCRA Company	\$ 13	<u>\$ 41</u>		

Consolidated Statement of Cash Flows

(Values in millions of USD unless noted)

	Three months er	ded March 31,
	2022	2021
Cash flows from operating activities:		
Consolidated net income	\$ 14	\$ 43
Adjustments to reconcile consolidated net income		
to net cash provided by operating activities:		
Depreciation and amortization	17	17
Amortization of bank financing costs	2	2
Share-based compensation		
Exchange rate changes on cash and cash equivalents		1
and restricted cash		
Undistributed (earnings) from investment in equity affiliates	(2)	(2)
(Gain) on sale of pipeline assets		(23)
Deferred income taxes		2
Pension expense, net of contributions		1
Return on investment in equity affiliates		3
Changes in assets and liabilities: (1)		
Receivables	(6)	(10)
Inventories	(1)	(17)
Other assets	5	(6)
Payables	(27)	8
Other liabilities	12	
Net cash provided by operating activities	15	27
Cash flows from investing activities:		
Capital expenditures	(2)	(2)
Proceeds from sale of pipeline assets		24
Net cash provided by (used in) investing activities	(2)	22
Cash flows from financing activities:		
Payments of short-term debt	_	(18)
Dividends paid to noncontrolling interest		(6)
Net cash (used in) financing activities		(24)
Net increase in cash and cash equivalents and restricted cash	13	25
Effect of exchange rate changes on cash		
and cash equivalents and restricted cash	_	(1)
Cash and cash equivalents and restricted cash at beginning of period	35_	118
Cash and cash equivalents and restricted cash at end of period	<u>\$ 48</u>	<u>\$ 142</u>

⁽¹⁾ Net of effect of translation

Consolidated Balance Sheet

(Values in millions of USD unless noted)

SD uniess noted				
A t	March	31, 2022	Decemb	er 31, 2021
Assets				
Current assets:				
Cash and cash equivalents	\$	46	\$	32
Restricted cash	Ψ	2	Ψ	3
Receivables, net		190		184
Inventories, net		240		239
Prepaid expenses and other current assets		37		43
Total current assets	X	515		501
		010		
Property, plant and equipment, net		317		329
Right of use lease assets, net		56		60
Goodwill		953	C	953
Other intangible assets, net		474		477
Investments in equity affiliates		168		166
Other assets		12		9
Total assets	\$	2,495	\$	2,495
Liabilities and Shareholder's Equity				
Current liabilities:				
Current debt	\$	50	\$	50
Lease liabilities, current portion	The second secon	4		5
Payables		118		134
Accrued and other current liabilities		91		75
Total current liabilities		263		264
				050
Long-term debt, net		944		952
Lease liabilities, long-term		30		31
Pension and other post-retirement benefit liabilities Other liabilities		8		8
		_		-
Deferred income tax liabilities	<u>+</u>	40	.	40
Total liabilities	<u>\$</u>	1,287	<u>\$</u>	1,302
Shareholder's equity:	<u>_</u>	1 002	<u>_</u>	1.000
Shareholder's equity	\$	1,083	\$	1,069
Accumulated other comprehensive income		27		27
Total The LYCRA Company shareholder's equity		1,110		1,096
Noncontrolling interest		98		97
Total shareholder's equity	<u>+</u>	1,208		1,193
Total liabilities and shareholder's equity	\$	2,495	\$	2,495

Management Adjusted EBITDA

(\$ in millions of USD unless noted)

	For the three months ended March 31,			
	2022	2021		
Consolidated net income	\$ 13.6	\$ 42.8		
Interest expense	19.7	19.6		
Income tax expense	3.1	12.5		
Depreciation and amortization	17.0	17.9		
EBITDA	53.4	92.8		
Joint venture EBITDA adjustment (a)	1.5	1.4		
Noncontrolling interest EBITDA ^(b)	(1.3)	(2.7)		
Foreign exchange adjustment ^(c)	0.2	(0.3)		
Foreign exchange on bonds ^(d)	(9.5)	(10.3)		
Other nonrecurring items ^(e)	• 0.2	0.6		
La Porte restructuring ^(f)	(2.6)	(28.4)		
Other restructuring ^(g)	7.0	—		
Impact of PRC functional currency ^(h)	0.5	_		
La Porte post-closure costs ⁽ⁱ⁾	—	3.9		
Financing costs ^(j)		0.4		
Adjusted EBITDA	\$ 49.4	\$ 57.4		
025				

Note: EBITDA and Adjusted EBITDA are not required by or presented in accordance with GAAP or any other internationally accepted accounting principles.

Management Adjusted EBITDA (cont.)

(Values in millions of USD unless noted)

- a) Represents an adjustment to conform The LYCRA Company's share of equity earnings associated with the Toray Opelontex Co., Ltd; ISH-Toray Pte. Ltd; and Shinpont Industry, Inc. joint ventures from net income to EBITDA.
- b) Represents the share of EBITDA attributable to the noncontrolling interest of The LYCRA Company Singapore Pte. Ltd.
- c) Represents foreign currency remeasurement relating to income taxes, most significantly in Brazil, Hong Kong, Switzerland, and the PRC.
- d) Represents the amount of foreign currency remeasurement on the Euro Notes.
- e) Represents certain other nonrecurring costs.
- f) Represents a reversal of certain accrued liabilities and recognition of income from the sale of pipeline assets at La Porte, net of costs associated with the transaction in March 2021.
- g) Represents accrued legal and advisory costs incurred for the Enforcement Action.
- h) Represents impacts from the foreign currency remeasurement losses primarily on intercompany activity with our operations in the PRC, whose functional currency is the Chinese yuan and whose currency translation impacts are reflected within Other Comprehensive Income.
- i) Represents costs incurred at La Porte following the cessation of operations in the fourth quarter of 2020.
- j) Represents one-time costs related to the Revolving Credit Facility during 2021.

Note: EBITDA and Adjusted EBITDA are not required by or presented in accordance with GAAP or any other internationally accepted accounting principles.